Lupin Appoints FMCG Veteran Anand Kripalu as Independent Director
Mumbai: Global pharma major Lupin Limited (Lupin) has announced the appointment of Anand Kripalu as an Independent Director. Anand Kripalu brings over three decades of leadership experience in the fast-moving consumer goods(FMCG) sector.
He currently serves as Executive Director of EPL Limited and previously served as its Managing Director and Global CEO until December 31, 2025. Prior to EPL, Anand held several distinguished leadership roles, including Managing Director and CEO at Diageo India and President – India and South-East Asia at Mondelez International (Cadbury). Earlier in his career, he spent more than 20 years at Unilever, where he held roles across senior general management, sales, and marketing across geographies.
Anand graduated from IIT Madras with a B.Tech in Electronics and earned an MBA from IIM Calcutta. He is a recipient of the Distinguished Alumnus Award from both schools and has also completed the Advanced Management Program at Wharton Business School. He currently serves as an Independent Director on the boards of Swiggy Limited and United Breweries Limited, having previously served as a director at Marico Limited.
Manju D Gupta, Chairman, Lupin said, “We are delighted to welcome Anand to the Board. His vast experience will be invaluable in advancing Lupin’s strategic priorities and reinforcing our position in the global pharmaceutical industry.”
Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 23,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries - Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.
